The Medicines and Healthcare products Regulatory Agency (MHRA) has approved gepotidacin (Blujepa), a new kind of oral antibiotic pill to treat uncomplicated

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday said it approved gepotidacin, also known as Blujepa, a new kind of oral antibiotic pill to treat uncomplicated urinary tract infections (UTIs) in females aged 12 years and older, who weigh at least 40 kg.

ACEP Now offers real-time clinical news, news from the American College of Emergency Physicians, and news on practice trends and health care reform for the emergency medicine physician. ACEP Now is an...

Crucial research by Neil Osheroff and his lab leads to approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name…

TUESDAY, April 15, 2025 A newly approved antibiotic to treat urinary tract infections may also help fight drug-resistant gonorrhea, a new study shows. The medic

Pamela Kushner, MD, offers insights on the newly approved antibiotic including its novel mechanism of action, the new criteria incorporated into the phase 3 studies, and what it means for her to have ...

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.

Après avoir démontré son efficacité, le nouvel antibiotique Blujepa développé par GSK a été approuvé par l’Agence américaine du médicament (FDA) pour les infections urinaires non compliquées à partir de 12 ans. Une femme sur deux présentera une cystite au cours de sa vie, dont un tiers aura une infection récurrente. Des alternatives antibiotiques sont nécessaires alors que le nombre d’infections urinaires par une bactérie avec une antibiorésistance augmente.